250 related articles for article (PubMed ID: 32941741)
1. Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study.
Chen J; Lin S; Niu C; Xiao Q
Expert Rev Respir Med; 2021 Feb; 15(2):257-265. PubMed ID: 32941741
[TBL] [Abstract][Full Text] [Related]
2. Shufeng Jiedu, a promising herbal therapy for moderate COVID-19:Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study.
Xia L; Shi Y; Su J; Friedemann T; Tao Z; Lu Y; Ling Y; Lv Y; Zhao R; Geng Z; Cui X; Lu H; Schröder S
Phytomedicine; 2021 May; 85():153390. PubMed ID: 33158717
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment.
Wang Z; Chen X; Lu Y; Chen F; Zhang W
Biosci Trends; 2020 Mar; 14(1):64-68. PubMed ID: 32037389
[TBL] [Abstract][Full Text] [Related]
4. Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19.
Liu L; Shi F; Tu P; Chen C; Zhang M; Li X; Li C
Medicine (Baltimore); 2021 Jan; 100(4):e24475. PubMed ID: 33530261
[TBL] [Abstract][Full Text] [Related]
5. Investigating the mechanism of ShuFeng JieDu capsule for the treatment of novel Coronavirus pneumonia (COVID-19) based on network pharmacology.
Chen X; Yin YH; Zhang MY; Liu JY; Li R; Qu YQ
Int J Med Sci; 2020; 17(16):2511-2530. PubMed ID: 33029094
[TBL] [Abstract][Full Text] [Related]
6. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study.
Deng L; Li C; Zeng Q; Liu X; Li X; Zhang H; Hong Z; Xia J
J Infect; 2020 Jul; 81(1):e1-e5. PubMed ID: 32171872
[TBL] [Abstract][Full Text] [Related]
7. [Overview of systematic reviews of Shufeng Jiedu Capsules].
Xu GQ; Zhao QL; Wang XY; Zhang D; Fan S; Zhang HQ; Wang MT; Chen MH; Liu M
Zhongguo Zhong Yao Za Zhi; 2022 Feb; 47(4):1103-1113. PubMed ID: 35285211
[TBL] [Abstract][Full Text] [Related]
8. [Systematic review and Meta-analysis of efficacy and safety of Shufeng Jiedu Capsules in treatment of influenza].
Zhou F; Zhao GZ; Li B; Xu XL; Shi YF; Mao YY; Tian JH; Liu QQ
Zhongguo Zhong Yao Za Zhi; 2023 Nov; 48(22):6216-6224. PubMed ID: 38114228
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR).
Pshenichnaya NY; Bulgakova VA; Lvov NI; Poromov AA; Selkova EP; Grekova AI; Shestakova IV; Maleev VV; Leneva IA
Ter Arkh; 2019 Mar; 91(3):56-63. PubMed ID: 31094461
[TBL] [Abstract][Full Text] [Related]
10. Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment.
Xin S; Cheng X; Zhu B; Liao X; Yang F; Song L; Shi Y; Guan X; Su R; Wang J; Xing L; Xu X; Jin L; Liu Y; Zhou W; Zhang D; Liang L; Yu Y; Yu R
Biomed Pharmacother; 2020 Sep; 129():110500. PubMed ID: 32768975
[TBL] [Abstract][Full Text] [Related]
11. Beneficial effect of Arbidol in the management of COVID-19 infection.
Jie X; Hongmei Y; Ping F; Kuikui Z; Bohan Y; Rui M
Aging (Albany NY); 2021 Apr; 13(7):9253-9264. PubMed ID: 33811756
[TBL] [Abstract][Full Text] [Related]
12. Potential therapeutic effect of Shufeng Jiedu capsule and its major herbs on coronavirus disease 2019 (COVID-19): A review.
Xu Y; Yang L; Wang L; Chen F
Drug Discov Ther; 2022 Jan; 15(6):289-299. PubMed ID: 34980761
[TBL] [Abstract][Full Text] [Related]
13. [Analysis on clinical study protocols of traditional Chinese medicine for coronavirus disease 2019].
Wang H; Jin XY; Pang B; Liu CX; Zheng WK; Yang FW; Pang WT; Zhang JH
Zhongguo Zhong Yao Za Zhi; 2020 Mar; 45(6):1232-1241. PubMed ID: 32281330
[TBL] [Abstract][Full Text] [Related]
14. Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID-19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series.
Gao W; Chen S; Wang K; Chen R; Guo Q; Lu J; Wu X; He Y; Yan Q; Wang S; Wang F; Jin L; Hua J; Li Q
Virol J; 2020 Oct; 17(1):162. PubMed ID: 33097047
[TBL] [Abstract][Full Text] [Related]
15. A systematic review and meta-analysis of the efficacy and safety of arbidol in the treatment of coronavirus disease 2019.
Wang X; Xie P; Sun G; Zhao M; Deng Z; Zhou Y; Bao S
Medicine (Baltimore); 2020 Jul; 99(30):e21402. PubMed ID: 32791753
[TBL] [Abstract][Full Text] [Related]
16. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study.
Lian N; Xie H; Lin S; Huang J; Zhao J; Lin Q
Clin Microbiol Infect; 2020 Jul; 26(7):917-921. PubMed ID: 32344167
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19.
Li M; Yu T; Zhu J; Wang Y; Yang Y; Zhao K; Yi Y; He J; Li C; He J
Ann Palliat Med; 2021 Mar; 10(3):3307-3312. PubMed ID: 33849115
[TBL] [Abstract][Full Text] [Related]
18. Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study.
Yin P; Meng J; Chen J; Gao J; Wang D; Liu S; Guo Q; Zhu M; Zhang G; Liu Y; Li Y; Zhang G
Virol J; 2021 Jul; 18(1):142. PubMed ID: 34238341
[TBL] [Abstract][Full Text] [Related]
19. Shufeng Jiedu capsule inhibits inflammation and apoptosis by activating A2AAR and inhibiting NF-κB to alleviate LPS-induced ALI.
Cai J; Wang YL; Sheng XD; Zhang L; Lv X
J Ethnopharmacol; 2022 Nov; 298():115661. PubMed ID: 36002086
[TBL] [Abstract][Full Text] [Related]
20. Traditional Chinese medicine as an adjunctive therapy for mild and common COVID-19: A systematic review and network meta-analysis.
Wu X; Li W; Qin Z; Xue L; Huang G; Luo Z; Chen Y
Medicine (Baltimore); 2021 Oct; 100(40):e27372. PubMed ID: 34622839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
